BR112018006005A2 - composto bicíclico e uso do mesmo para inibição de suv39h2 - Google Patents

composto bicíclico e uso do mesmo para inibição de suv39h2

Info

Publication number
BR112018006005A2
BR112018006005A2 BR112018006005A BR112018006005A BR112018006005A2 BR 112018006005 A2 BR112018006005 A2 BR 112018006005A2 BR 112018006005 A BR112018006005 A BR 112018006005A BR 112018006005 A BR112018006005 A BR 112018006005A BR 112018006005 A2 BR112018006005 A2 BR 112018006005A2
Authority
BR
Brazil
Prior art keywords
suv39h2
inhibition
bicyclic compound
bicyclic
compound
Prior art date
Application number
BR112018006005A
Other languages
English (en)
Inventor
Chakrabarti Anjan
Talukdar Arindam
Venkata Satyanarayana Arvapalli
Decornez Helene
Rawat Manish
Rai Sanjay
Hisada Shoji
H Ravula Srinivas
Matsuo Yo
Nakamura Yusuke
Duan Zhiyong
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BR112018006005A2 publication Critical patent/BR112018006005A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

a presente invenção refere-se a um composto representado pela fórmula (i).
BR112018006005A 2015-09-29 2016-09-12 composto bicíclico e uso do mesmo para inibição de suv39h2 BR112018006005A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562234183P 2015-09-29 2015-09-29
PCT/US2016/051350 WO2017058503A1 (en) 2015-09-29 2016-09-12 Bicyclic compound and use thereof for inhibiting suv39h2

Publications (1)

Publication Number Publication Date
BR112018006005A2 true BR112018006005A2 (pt) 2018-10-30

Family

ID=58427860

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018006005A BR112018006005A2 (pt) 2015-09-29 2016-09-12 composto bicíclico e uso do mesmo para inibição de suv39h2

Country Status (17)

Country Link
US (1) US10508109B2 (pt)
EP (1) EP3355699B1 (pt)
JP (1) JP6827621B2 (pt)
KR (1) KR20180082432A (pt)
CN (1) CN108135175B (pt)
AU (2) AU2016332021A1 (pt)
BR (1) BR112018006005A2 (pt)
CA (1) CA2999852A1 (pt)
DK (1) DK3355699T3 (pt)
ES (1) ES2874089T3 (pt)
HK (1) HK1252428A1 (pt)
IL (1) IL258328B (pt)
MX (1) MX2018003903A (pt)
RU (1) RU2729187C1 (pt)
SG (1) SG10202002831RA (pt)
TW (1) TWI696622B (pt)
WO (1) WO2017058503A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4143177A1 (en) * 2020-04-30 2023-03-08 Syngenta Crop Protection AG Pesticidally active heterocyclic derivatives with sulfur containing substituents
CA3190065A1 (en) * 2020-08-19 2022-02-24 David S. Yoon Imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis
CN113304151B (zh) * 2021-04-15 2022-05-03 中山大学 一种硝基呋喃类小分子化合物在制备诱导铁死亡和/或减缓胃癌化疗耐药药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC1673A1 (fr) 1984-06-27 1986-06-03 Wellcome Found Derives aryliques de composes imidazoliques,leur preparation et leur emploi pour la preparation des medicaments
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
WO2004031410A2 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
TWI350373B (en) 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
ES2379805T3 (es) 2005-07-27 2012-05-03 Oncotherapy Science, Inc. ECT2 como diana terapéutica del cáncer de esófago
WO2009054497A1 (ja) * 2007-10-26 2009-04-30 Nihon Medi-Physics Co., Ltd. 新規アミロイド親和性化合物
AU2008323287B2 (en) * 2007-11-14 2011-07-14 Addex Pharma S.A. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
FR2928922B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
BRPI0822685A2 (pt) * 2008-05-14 2015-06-30 Otsuka Pharma Co Ltd Composições de ativação de lipoproteína lipase compreendendo derivados de benzeno
BR112013013417A2 (pt) 2010-11-30 2019-09-24 Takeda Pharmaceuticals Co composto, medicamento, métodos para inibir a acetil-coa carboxilase em um mamífero, e de profilaxia ou tratamento da obesidade ou diabete em um mamífero, e, uso de um composto ou sal
US8975276B2 (en) * 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10
ES2624453T3 (es) * 2013-04-29 2017-07-14 F. Hoffmann-La Roche Ag Derivados de 2-fenil o 2-hetaril-imidazol[1,2-a]piridina
SG11201509503QA (en) * 2013-05-23 2015-12-30 Hoffmann La Roche 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
US20160120863A1 (en) 2013-05-24 2016-05-05 Iomet Pharma Ltd. Slc2a transporter inhibitors
JP6677637B2 (ja) * 2013-07-02 2020-04-08 シンジェンタ パーティシペーションズ アーゲー 有害生物防除的に活性な、硫黄含有置換基を有する二環式または三環式複素環

Also Published As

Publication number Publication date
RU2729187C1 (ru) 2020-08-05
AU2021201573A1 (en) 2021-04-01
TW201718580A (zh) 2017-06-01
KR20180082432A (ko) 2018-07-18
HK1252428A1 (zh) 2019-05-24
MX2018003903A (es) 2018-09-21
TWI696622B (zh) 2020-06-21
DK3355699T3 (da) 2021-06-07
WO2017058503A1 (en) 2017-04-06
AU2021201573B2 (en) 2022-02-17
CN108135175B (zh) 2021-04-06
CA2999852A1 (en) 2017-04-06
CN108135175A (zh) 2018-06-08
AU2016332021A1 (en) 2018-04-19
IL258328A (en) 2018-05-31
EP3355699A1 (en) 2018-08-08
JP6827621B2 (ja) 2021-02-10
EP3355699B1 (en) 2021-03-31
ES2874089T3 (es) 2021-11-04
US20180273529A1 (en) 2018-09-27
SG10202002831RA (en) 2020-05-28
US10508109B2 (en) 2019-12-17
IL258328B (en) 2021-05-31
JP2018531244A (ja) 2018-10-25
EP3355699A4 (en) 2019-06-19

Similar Documents

Publication Publication Date Title
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
PH12018501096A1 (en) Modulators of chemokine receptors
EA201692219A1 (ru) Способы получения противовирусных соединений
SG10201809518QA (en) Processes of preparing a jak1 inhibitor and new forms thereto
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
CR20150541A (es) Compuestos y composiciones nuevos para la inhibición de fasn
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
CU20190006A7 (es) Composiciones para inhibir masp-3
DK3066085T3 (da) Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor
UY36330A (es) Compuestos inhibidores de quinasa de unión a tank
CR20170315A (es) Inhibridores bace 1 selectivos
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
MX2022010755A (es) Inhibidores de quinasa y usos de los mismos.
CR20170005A (es) Derivados de insoindolina
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
MX2016010973A (es) Compuestos de aminocarbonilcarbamato.
MX2017014549A (es) Farmacos precursores de oxabicicloheptanos.
BR112015019924A2 (pt) métodos e composições para tratar leucemia
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
BR112018006005A2 (pt) composto bicíclico e uso do mesmo para inibição de suv39h2

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 43/90

Ipc: C07D 451/00 (2006.01), C07D 471/04 (2006.01), C07D

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time